CANCER:

Spindle Cell Sarcoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

NTRK1 fusion	Spindle Cell Sarcoma	NTRK1 fusion	Spindle Cell Sarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion	Spindle Cell Sarcoma	NTRK3 fusion	Spindle Cell Sarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
KRAS G12V	Spindle Cell Sarcoma	KRAS G12V	Spindle Cell Sarcoma	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3
SMARCB1 negative	Spindle Cell Sarcoma	SMARCB1 negative	Spindle Cell Sarcoma	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3	tazemetostat Sensitive: C3 – Early Trials tazemetostat Sensitive : C3
TPM3-NTRK1 fusion	Spindle Cell Sarcoma	TPM3-NTRK1 fusion	Spindle Cell Sarcoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
KIAA1549-BRAF fusion + PTEN deletion	Spindle Cell Sarcoma	KIAA1549-BRAF fusion + PTEN deletion	Spindle Cell Sarcoma	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4	bevacizumab + sorafenib + temsirolimus Sensitive: C4 – Case Studies bevacizumab + sorafenib + temsirolimus Sensitive : C4
QKI-RAF1 fusion	Spindle Cell Sarcoma	QKI-RAF1 fusion	Spindle Cell Sarcoma	trametinib Sensitive: C4 – Case Studies trametinib Sensitive : C4	trametinib Sensitive: C4 – Case Studies trametinib Sensitive : C4
QKI-RAF1 fusion	Spindle Cell Sarcoma	QKI-RAF1 fusion	Spindle Cell Sarcoma	temozolomide + irinotecan Resistant: C4 – Case Studies temozolomide + irinotecan Resistant : C4	temozolomide + irinotecan Resistant: C4 – Case Studies temozolomide + irinotecan Resistant : C4